PD-L1 profiling of circulating tumor cells for immune checkpoint inhibitor therapy in head and neck cancers

被引：0

作者：

Patil, Revati ^{[1
]}

Akolkar, Dadasaheb B. ^{[1
]}

Patil, Darshana ^{[1
]}

Devhare, Pradip ^{[1
]}

Srivastava, Navin ^{[1
]}

Fulmali, Pooja ^{[1
]}

Patel, Shoeb ^{[1
]}

Shejwalkar, Pradyumna ^{[1
]}

Datta, Vineet ^{[1
]}

Sims, Cynthe ^{[1
]}

Srinivasan, Ajay ^{[1
]}

Datar, Rajan ^{[1
]}

机构：

[1] Datar Canc Genet Ltd, Nasik, India

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[31] The circulating PD-L1: An emerging predictive biomarker for immune checkpoint inhibitors response
Chovet, Fanny
Passot, Anne-Sophie
Mangon, Quentin
Rouzaire, Paul
Douge, Aurore
BULLETIN DU CANCER, 2024, 111 (04) : 416 - 427
[32] The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang, Qing
Chen, Yun
Li, Xiaojuan
Long, Shunqin
Shi, Yao
Yu, Yaya
Wu, Wanyin
Han, Ling
Wang, Sumei
FRONTIERS IN IMMUNOLOGY, 2022, 13
[33] PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
Kleinovink, Jan Willem
Marijt, Koen A.
Schoonderwoerd, Mark J. A.
van Hall, Thorbald
Ossendorp, Ferry
Fransen, Marieke F.
ONCOIMMUNOLOGY, 2017, 6 (04):
[34] Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
Burcher, Kimberly M.
Lantz, Jeffrey W.
Gavrila, Elena
Abreu, Arianne
Burcher, Jack T.
Faucheux, Andrew T.
Xie, Amy
Jackson, Clayton
Song, Alexander H.
Hughes, Ryan T.
Lycan, Thomas, Jr.
Bunch, Paul M.
Furdui, Cristina M.
Topaloglu, Umit
D'Agostino, Ralph T. B., Jr.
Zhang, Wei
Porosnicu, Mercedes
CANCERS, 2021, 13 (22)
[35] Interspatial Distribution of Tumor and Immune Cells in Correlation with PD-L1 in Molecular Subtypes of Gastric Cancers
Dislich, Bastian
Mertz, Kirsten D.
Gloor, Beat
Langer, Rupert
CANCERS, 2022, 14 (07)
[36] Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
Ruiting Li
Xiaojing Zou
Huaqing Shu
You Shang
Intensive Care Research, 2021, 1 (1-2): : 11 - 15
[37] IMPDH inhibitors upregulate PD-L1 in cancer cells without impairing immune checkpoint inhibitor efficacy
Zheng, Ming-ming
Li, Jia-yi
Guo, Hong-jie
Zhang, Jie
Wang, Long-sheng
Jiang, Ke-fan
Wu, Hong-hai
He, Qiao-jun
Ding, Ling
Yang, Bo
ACTA PHARMACOLOGICA SINICA, 2024, : 1058 - 1067
[38] Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Placke, Jan-Malte
Soun, Camille
Bottek, Jenny
Herbst, Rudolf
Terheyden, Patrick
Utikal, Jochen
Pfoehler, Claudia
Ulrich, Jens
Kreuter, Alexander
Pfeiffer, Christiane
Mohr, Peter
Gutzmer, Ralf
Meier, Friedegund
Dippel, Edgar
Weichenthal, Michael
Zimmer, Lisa
Livingstone, Elisabeth
Becker, Juergen C.
Lodde, Georg
Sucker, Antje
Griewank, Klaus
Horn, Susanne
Hadaschik, Eva
Roesch, Alexander
Schadendorf, Dirk
Engel, Daniel Robert
Ugurel, Selma
FRONTIERS IN ONCOLOGY, 2021, 11
[39] Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth
Rawangkan, Anchalee
Wongsirisin, Pattama
Namiki, Kozue
Iida, Keisuke
Kobayashi, Yasuhito
Shimizu, Yoshihiko
Fujiki, Hirota
Suganuma, Masami
MOLECULES, 2018, 23 (08)
[40] Oral immune checkpoint antagonists targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy
Sasikumar, Pottayil
Sudarshan, N. S.
Gowda, Nagaraj
Samiulla, D. S.
Ramachandra, Raghuveer
Chandrasekhar, T.
Adurthi, Sreenivas
Mani, Jiju
Nair, Rashmi
Singh, Sharad
Dhudashia, Amit
Gowda, Nagesh
Ramachandra, Murali
CANCER RESEARCH, 2016, 76

← 1 2 3 4 5 →